Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 16/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.55 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14499226 | 0.95 | TBXAS1 (0.60) | TBXAS1ALDH1A1ABL1RIN1EGLN3 | |
| SCHEMBL9716291 | 0.94 | TBXAS1 (0.63) | TBXAS1ALDH1A1ABL1RIN1 | |
| SCHEMBL11572618 | 0.94 | TBXAS1 (0.63) | TBXAS1ALDH1A1ABL1RIN1 | |
| SCHEMBL47374 | 0.90 | TBXAS1 (0.59) | TBXAS1ALDH1A1ABL1RIN1EGLN3 | |
| SCHEMBL7818459 | 0.88 | TBXAS1 (0.52) | TBXAS1ALDH1A1ABL1RIN1EGLN3 | |
| SCHEMBL6136437 | 0.86 | ALDH1A1 (0.51) | TBXAS1ALDH1A1ABL1RIN1 | |
| SCHEMBL7824835 | 0.84 | TBXAS1 (0.55) | TBXAS1ALDH1A1ABL1RIN1 | |
| SCHEMBL26528214 | 0.84 | TBXAS1 (0.57) | TBXAS1ALDH1A1EGLN3 | |
| SCHEMBL9786222 | 0.84 | TBXAS1 (0.69) | TBXAS1ALDH1A1 | |
| SCHEMBL9459688 | 0.82 | TBXAS1 (0.62) | TBXAS1ALDH1A1ABL1RIN1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113979946-B | Carboxyl imidazole proton ionic liquid and preparation method and application thereof | 中国科学院兰州化学物理研究所 | 2023-05-09 | — | — | CN | disclosed |
| CN-113979946-A | Carboxyl imidazole proton type ionic liquid and preparation method and application thereof | 中国科学院兰州化学物理研究所 | 2022-01-28 | — | — | CN | disclosed |
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-7754750-B2 | a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-20100113460-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100113460-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100113460-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| EP-2139354-A2 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20080306065-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1676846-A2 | Hydantoin derivatives as MMP inhibitors | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040127528-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | US | disclosed |
| EP-0354539-B1 | Antiinflammatory carbinoloimidazoles | DU PONT MERCK PHARMA (US) | 1995-04-05 | — | — | EP | disclosed |
| US-5103007-A | Antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5081245-A | Selective antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-01-14 | — | — | US | disclosed |
| EP-0378763-A1 | Lipids, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-07-25 | — | — | EP | disclosed |
| EP-0356765-A2 | Carboxylic acid derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-03-07 | — | — | EP | disclosed |
| EP-0354539-A2 | Antiinflammatory carbinoloimidazoles | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1990-02-14 | — | — | EP | disclosed |
| US-4859693-A | Antiinflammatory carbinoloimidazoles | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | TBXAS1 522/4885ALDH1A1 612/4885ABL1 1840/4885 |
| US-20100113460-A1 | Organic Compounds | CYP2B6, CYP2A6, CYP2A13 | TBXAS1 406/4885ALDH1A1 78/4885ABL1 1740/4885 |
| US-20080306065-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | TBXAS1 522/4885ALDH1A1 612/4885ABL1 1840/4885 |
| US-20040127528-A1 | Metalloproteinase inhibitors | MMP9, MMP10, MMP3 | TBXAS1 737/4885ALDH1A1 573/4885ABL1 3392/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | TBXAS1 1327/4885ALDH1A1 1250/4885ABL1 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.